PFE · News · 20260903N

COVID Product Demand Decline

PFIZER INC · 2026-09-03 · Importance 26 · Surprise 24

Pfizer continues to face weakening demand for its COVID-19 products, including Comirnaty, as the pandemic-related revenue contribution normalizes. Third-party reporting identifies lower COVID product sales as a key offset to growth from newer and acquired medicines. Patent expirations are expected to add further pressure to Pfizer’s overall product demand and revenue mix.

Key facts

• Pfizer expects a decline from 2025 revenues due to lower COVID-19 product sales and patent expirations. source